BRAF and MEK are proteins involved in a cell-signaling pathway called the MAPK pathway. Melanomas that harbor mutations in BRAF respond to BRAF and MEK inhibitors; however, almost all of them develop resistance to these drugs within months.
MRV Research
Merck: Advanced melanoma patients treated with MK-3475 showed 81% survival at 1 year
Patients with advanced melanoma had an overall survival rate of 81% at 1 year across all monotherapy doses of an investigational anti-PD-1 immunotherapy, Merck has announced.
Talimogene laherparepvec showed favorable results in patients with metastatic melanoma
Patients with metastatic melanoma treated with talimogene laherparepvec experienced longer overall survival than those treated with granulocyte-macrophage colony-stimulating factor in a phase 3 study, according to results released by Amgen.
The Society for Melanoma Research and Prova Education Collaborate to Expand the 10th Anniversary Congress
More than 650 health care professionals are expected to attend the 10th Anniversary Society for Melanoma Research (SMR) Congress to learn about cutting edge research and advances in clinical care for melanoma.